The proposed project aims at developing a novel therapeutic intervention against chronic hepatitis B, which currently remains a significant public health challenge worldwide. We will explore the development of a group of newly identified compounds that inhibit the formation of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which is not targeted by current available antiviral medications. HBV cccDNA plays a central role in viral infection establishment and persistence, and is the basis for the failure of current antiviral treatments and virus rebound after the cessation of therapy. Therefore the elimination of cccDNA is the ultimate goal in curing HBV infection. Through our efforts to screen an 80,300 small molecule library using an innovative cell-based cccDNA high throughput assay, two structurally related disubstituted-sulfonamides (DSS) were discovered that have dramatic inhibition of cccDNA formation by interfering with the deproteinization of HBV genomic relaxed circular (rc) DNA, which serves as the intermediate precursor for cccDNA. To determine whether Investigational New Drug (IND)-enabling studies are justified, we plan to optimize these compounds, assess their utility against drug resistant infections and in combination with existing drugs in vitro, determine their in vivo characteristics and efficacy, and further study their mechanism of action. Successful completion of our goals will produce at least one new lead to advanced preclinical studies.

Public Health Relevance

Hepatitis B virus (HBV) infection is a severe public health problem affecting about 350 million individuals worldwide. Chronic hepatitis B patients have a high risk of occurrence of hepatocirrhosis and liver cancer. Currently approved drugs for treatment of chronic hepatitis B, including alpha interferon, and nucleos(t)ide analogues inhibiting the viral polymerase, are limited by poor response, side effects and emergence of drug resistance. In our proposal, we are aiming at the development of a non-classical anti-HBV agent with novel antiviral target. Our research is thus highly related to the public health interest. The accomplishment of proposed research will ultimately lead to the better therapeutic for the management of hepatitis B disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-FDS-M (J2))
Program Officer
Koshy, Rajen
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Drexel University
Schools of Medicine
United States
Zip Code
Wei, Xia-Fei; Gan, Chun-Yang; Cui, Jing et al. (2018) Identification of Compounds Targeting Hepatitis B Virus Core Protein Dimerization through a Split Luciferase Complementation Assay. Antimicrob Agents Chemother 62:
Alter, Harvey; Block, Timothy; Brown, Nathaniel et al. (2018) A research agenda for curing chronic hepatitis B virus infection. Hepatology 67:1127-1131
Mitra, Bidisha; Thapa, Roshan J; Guo, Haitao et al. (2018) Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. Antiviral Res 158:185-198
Cai, Xiaodan; Zheng, Weihao; Pan, Shaokun et al. (2018) A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. Antiviral Res 149:48-57
Liu, Shi; Zhou, Bin; Valdes, Juan D et al. (2018) Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology :
Mani, Nagraj; Cole, Andrew G; Phelps, Janet R et al. (2018) Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. Antimicrob Agents Chemother 62:
Long, Quanxin; Yan, Ran; Hu, Jieli et al. (2017) The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog 13:e1006784
Iwamoto, Masashi; Cai, Dawei; Sugiyama, Masaya et al. (2017) Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication. Sci Rep 7:10620
Liu, Yuanjie; Nie, Hui; Mao, Richeng et al. (2017) Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog 13:e1006296
Hong, Xupeng; Kim, Elena S; Guo, Haitao (2017) Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology 66:2066-2077

Showing the most recent 10 out of 28 publications